Education
About Us
Working with TipRanks
Follow Us
Zyversa Therapeutics, Inc. (ZVSA)
:ZVSA
Total Valuation
ZyVersa Therapeutics has a market cap or net worth of $1.19M. The enterprise value is $3.19M.
Market Cap$1.19M
Enterprise Value$3.19M
Share Statistics
ZyVersa Therapeutics has 8,095,921 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,095,921
Owned by Insiders6.64%
Owned by Institutions0.22%
Financial Efficiency
ZyVersa Therapeutics’s return on equity (ROE) is -1.11K and return on invested capital (ROIC) is -97461.45%.
Return on Equity (ROE)-1.11K
Return on Assets (ROA)-456.98
Return on Invested Capital (ROIC)-97461.45%
Return on Capital Employed (ROCE)-975.31
Revenue Per Employee0.00
Profits Per Employee-1.34M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ZyVersa Therapeutics is ―. ZyVersa Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.14
Price to FCF―
Price to Operating Cash Flow>-0.01
PEG Ratio―
Income Statement
In the last 12 months, ZyVersa Therapeutics had revenue of 0.00 and earned -9.41B in profits. Earnings per share was -8.48.
Revenue0.00
Gross Profit-6.93K
Operating Income-9.14B
Pretax Income-9.42B
Net Income-9.41B
EBITDA-9.14B
Earnings Per Share (EPS)-8.48
Cash Flow
In the last 12 months, operating cash flow was -9.62B and capital expenditures 0.00, giving a free cash flow of -6.37B billion.
Operating Cash Flow-9.62B
Free Cash Flow-6.37B
Free Cash Flow per Share-787.26
Dividends & Yields
ZyVersa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change-95.27%
50-Day Moving Average0.39
200-Day Moving Average0.84
Relative Strength Index (RSI)32.22
Average Volume (3m)679.21K
Important Dates
ZyVersa Therapeutics upcoming earnings date is Nov 12, 2025, Before Open (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 12, 2025
Ex-Dividend Date―
Financial Position
ZyVersa Therapeutics as a current ratio of 0.15, with Debt / Equity ratio of 0.00%
Current Ratio0.15
Quick Ratio0.15
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio-33.86K
Taxes
In the past 12 months, ZyVersa Therapeutics has paid -6.75M in taxes.
Income Tax-6.75M
Effective Tax Rate<0.01
Enterprise Valuation
ZyVersa Therapeutics EV to EBITDA ratio is <0.01, with an EV/FCF ratio of 0.05.
EV to Sales0.00
EV to EBITDA<0.01
EV to Free Cash Flow0.05
EV to Operating Cash Flow0.05
Balance Sheet
ZyVersa Therapeutics has $72.09M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$72.09M billion.
Cash & Marketable Securities$72.09M
Total Debt$0.00
Net Cash-$72.09M
Net Cash Per Share-$8.90
Tangible Book Value Per Share-$9.13
Margins
Gross margin is 43.35%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin43.35%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ZyVersa Therapeutics is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$20.00
Price Target Upside14185.71% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast93.34%